HMDCF (HUTCHMED (China)) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HMDCF HUTCHMED (China) Ltd HMDCF
68 GF Score
Price $2.16
GF Value $2.66
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is HUTCHMED (China) Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

HMDCF
68GF Score
HUTCHMED (China) Ltd HMDCF
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is HUTCHMED (China) (HMDCF) Overvalued in 2026?

Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued. The current stock price of $2.16 is trading 18.8% below its estimated GF Value™ of $2.66. GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.

Key valuation signals for HMDCF:

  • Dividend-Payout-to-FFO:
  • GF Value™: $2.66 vs. price of $2.16 (18.8% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HUTCHMED (China) Business Description

Address 2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
68GF Score

Get the complete analysis for HMDCF

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$2.66
GF Value